Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer

Kyeong-Hyun KIM; Seo-Young SONG; Kyu-Hyoung LIM; Seon-Sook HAN; Se-Hyun KIM; Jun-Hwi CHO; Chan-Woo PARK; Seoungkoo LEE; Hui-Young LEE.
Cancer Research and Treatment ; : 74-77, 2013.
Artículo en Inglés | WPRIM | ID: wpr-213728

Documentos relacionados

  1. Immunoglobulins as a treatment modality for corticosteroid-refractory pemetrexed-induced interstitial lung disease, case report.
  2. Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer).
  3. Acute diffuse interstitial lung disease in adults: Do not overlook lepidic adenocarcinoma of the lung.
  4. [The virtual ILD board: a pilot project].
  5. Anti-PM-Scl antibodies-positive patients encompass three different groups with distinct prognoses.
  6. Interstitial Lung Disease: Not So Fast.
  7. Differential diagnostics of interstitial lung diseases.
  8. Assessing the acceptability and feasibility of remote spirometric monitoring for rural patients with interstitial lung disease: a multimethod approach.
  9. Real-world evaluation of second line chemotherapy for patients with advanced non-small cell lung cancer harboring preexisting interstitial lung disease.
  10. [Pulmonology 2021: year in review].